95 studies found for:    "mucopolysaccharidosis type IV"
Show Display Options
Rank Status Study
21 Active, not recruiting BMN 110 Phase 3B in Australian Patients
Condition: Mucopolysaccharidosis IVA (Morquio A Syndrome)
Intervention: Drug: BMN 110
22 Active, not recruiting Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial
Condition: Rubinstein-Taybi Syndrome
Interventions: Drug: sodium valproate;   Drug: Placebo
23 Not yet recruiting Growth Hormone for Osteoporosis Pseudoglioma Syndrome
Condition: Osteoporosis Pseudoglioma Syndrome
Intervention: Biological: Human recombinant growth hormone
24 Completed A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers
Condition: Achondroplasia
Interventions: Drug: BMN 111;   Drug: Normal Saline
25 Active, not recruiting Growth Hormone Therapy in Osteogenesis Imperfecta
Condition: Osteogenesis Imperfecta
Intervention: Other: Growth hormone
26 Completed Bisphosphonate Therapy for Osteogenesis Imperfecta
Conditions: Osteogenesis Imperfecta;   Osteoporosis;   Paget Disease of Bone
Interventions: Drug: Alendronate;   Drug: Pamidronate
27 Completed Immune Response in the SAPHO Syndrome
Condition: SAPHO Syndrome
Intervention:
28 Active, not recruiting An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
Condition: Osteogenesis Imperfecta
Intervention: Drug: Zoledronic Acid
29 Active, not recruiting Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome
Condition: Osteoporosis Pseudoglioma
Intervention: Drug: Lithium
30 Terminated A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement
Conditions: Osteoarthritis;   Post-traumatic Arthritis;   Collagen Disorders;   Avascular Necrosis;   Traumatic Femoral Fractures;   Nonunion of Femoral Fractures;   Congenital Hip Dysplasia;   Slipped Capital Femoral Epiphysis;   Perthes Disease
Interventions: Device: Future Hip;   Device: Omniflex;   Device: Zueymüller;   Device: CLS Spotorno
31 Terminated A Multi-centre Study to Assess the Long-term Performance of the Summit™ Hip in Primary Total Hip Replacement
Conditions: Rheumatoid Arthritis;   Osteoarthritis;   Post-traumatic Arthritis;   Collagen Disorders;   Avascular Necrosis;   Traumatic Femoral Fractures;   Nonunion of Femoral Fractures;   Congenital Hip Dysplasia;   Slipped Capital Femoral Epiphysis
Intervention: Device: Summit Tapered Hip System
32 Active, not recruiting C-Type Natriuretic Peptide and Achondroplasia
Conditions: Achondroplasia;   Hypochondroplasia
Intervention:
33 Unknown  Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis
Condition: Osteopetrosis
Interventions: Drug: Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen);   Procedure: Stem Cell Transplantation;   Drug: Cyclosporin, Methotrexate (GVHD prophylaxis)
34 Active, not recruiting Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab
Condition: Osteogenesis Imperfecta
Intervention: Drug: Denosumab
35 Completed Issues Surrounding Prenatal Genetic Testing for Achondroplasia
Conditions: Achondroplasia;   Dwarfism
Intervention:
36 Unknown  Histamine Responsiveness in McCune-Albright Syndrome
Condition: McCune-Albright Syndrome
Intervention:
37 Terminated
Has Results
Reduced Intensity AlloTransplant For Osteopetrosis
Condition: Osteopetrosis
Interventions: Procedure: Stem Cell or Umbilical Cord Blood Transplantation;   Drug: Campath, Busulfan, Clofarabine;   Procedure: Total Lymphoid Irradiation
38 Completed Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
Condition: Osteogenesis Imperfecta
Interventions: Other: Bone Marrow Cell Transplantation;   Radiation: Irradiation, Total Body;   Drug: Cyclophosphamide;   Drug: Cyclosporin;   Procedure: Mesenchymal Stem Cell Transplantation;   Drug: Busulfan
39 Completed Natural History of Asphyxiating Thoracic Dystrophy (DTJ)
Condition: Asphyxiating Thoracic Dystrophy
Intervention: Genetic: IFT80 screening
40 Unknown  Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Conditions: Bone Marrow Failure;   Osteopetrosis;   Fanconi Anemia;   Severe Combined Immunodeficiency
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide 40;   Drug: Cyclophosphamide 30

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years